28 research outputs found
BASE-STEP: A transportable antiproton reservoir for fundamental interaction studies
Currently, the only worldwide source of low-energy antiprotons is the
AD/ELENA facility located at CERN. To date, all precision measurements on
single antiprotons have been conducted at this facility and provide stringent
tests of the fundamental interactions and their symmetries. However, the
magnetic field fluctuations from the facility operation limit the precision of
upcoming measurements. To overcome this limitation, we have designed the
transportable antiproton trap system BASE-STEP to relocate antiprotons to
laboratories with a calm magnetic environment. We anticipate that the
transportable antiproton trap will facilitate enhanced tests of CPT invariance
with antiprotons, and provide new experimental possibilities of using
transported antiprotons and other accelerator-produced exotic ions. We present
here the technical design of the transportable trap system. This includes the
transportable superconducting magnet, the cryogenic inlay consisting of the
trap stack and the detection systems, and the differential pumping section to
suppress the residual gas flow into the cryogenic trap chamber.Comment: To be submitted to Rev. Sci. Instrument
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients
OBJECTIVE: The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphineâpretreated STâelevation myocardial infarction (STEMI) patients. METHODS: In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60Â mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)âinduced platelet aggregation was measured at four time points: at baseline, and at 2Â h, 1Â day and 2Â days after prasugrel loading. RESULTS: Morphine use was associated with a threeâfold higher level of ADPâinduced platelet aggregation 2Â h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADPâinduced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high onâtreatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17â20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 â 2. CONCLUSION: The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine